Still a lot of maybes
Staff work in the Laboratories of BSP Pharmaceuticals, where about 100,000 doses per month of Bamlanivimab Lilly, monoclonal antibodies, are produced on behalf of Lilly pharmaceutical company, to fight COVID-19, in Latina, Italy, 21st December 2020.
Monoclonal antibody therapies have helped prevent hospitalizations and severe symptoms in high-risk coronavirus patients. But recent viral mutations may render them ineffective. [ more › ]






You must be logged in to post a comment.